Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis

Launched by AZIENDA OSPEDALIERO, UNIVERSITARIA OSPEDALI RIUNITI · Oct 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how effective a special imaging test called cardiac magnetic resonance (CMR) is in helping doctors manage treatment for patients with recurrent pericarditis who are being treated with a medication called anakinra. Recurrent pericarditis is a condition where the lining around the heart becomes inflamed multiple times. The goal is to see if using CMR imaging provides better guidance for treatment compared to just checking a blood test called C-reactive protein (CRP), which measures inflammation in the body.

To participate in this trial, you need to be an adult who is at least 18 years old or a child who is under 18 and receiving the appropriate dose of anakinra for your condition. You must have had recurrent pericarditis that hasn’t improved with other treatments like steroids or certain anti-inflammatory drugs. If you are currently dealing with an ongoing infection or would prefer not to take part in the study, you won't be eligible. Participants in this trial can expect to undergo CMR imaging and routine monitoring while receiving their treatment, which may help improve how their condition is managed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients treated with anakinra 100 mg/die if ≥ 18 years old, and
• • Pediatric patients treated with anakinra 2 mg/kg/die if \< 18 years old
• • Pediatric and adult patients treated with anakinra due to corticosteroid-dependent or not responsive to colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) recurrent pericarditis
• Exclusion Criteria:
• • Ongoing infection (proved within serology)
• • Refuse to participate in the trial